Alkermes plc (Nasdaq: ALKS), a global biopharmaceutical company, announced on Friday that it has named Richard Gaynor, MD and Frank Anders (Andy) Wilson as new directors.
Presently, Dr Gaynor serves as the president of Research & Development at Neon Therapeutics. He joined Neon Therapeutics in 2016 as its president of Research and Development. Prior to joining Neon, he started his industry career at Eli Lilly and Company, where he spent 15 years in clinical development and medical affairs roles, including as senior vice president, Clinical Development and Medical Affairs of Lilly Oncology.
Wilson most recently served as chief financial officer of PerkinElmer Inc. Prior to joining PerkinElmer Inc, he held key business development and finance roles for more than 12 years at Danaher Corporation including corporate vice president of Investor Relations. Prior to Danaher, he worked for several years at AlliedSignal Inc, now Honeywell International Inc, as vice resident of Finance and chief financial officer for the Commercial Avionics Systems division. He has served as a member of the board of directors of Cabot Corporation since 2018.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886